Related Experiment Video

Updated: Jun 4, 2026

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells

Zhimin Zhou1, Lihua Sun, Yingyi Wang

  • 1Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, People's Republic of China.

Cancer Biotherapy & Radiopharmaceuticals
|March 2, 2011
PubMed

Insights

Bone morphogenetic protein 4 (BMP4) inhibits glioma stem cell (GSC) proliferation and promotes apoptosis. This suggests BMP4 as a potential therapeutic target for glioma treatment.

Area of Science:

  • Neuro-oncology
  • Stem Cell Biology
  • Molecular Biology

Background:

  • Glioma stem cells (GSCs) drive glioma, a prevalent central nervous system malignancy.
  • Bone morphogenetic protein 4 (BMP4) is known to regulate neural stem cell differentiation and proliferation.

Purpose of the Study:

  • To investigate the role and mechanisms of BMP4 in regulating glioma stem cells.
  • To explore BMP4 as a potential therapeutic strategy for glioma.

Main Methods:

  • Glioma stem cells (GSCs) were isolated from U87 human glioma cells.
  • GSCs were treated with bone morphogenetic protein 4 (BMP4) protein.

Main Results:

  • BMP4 significantly inhibited U87 GSC proliferation (p < 0.01) by downregulating cyclin D1.
  • BMP4 promoted GSC apoptosis by inducing Bax and inhibiting Bcl-2 and Bcl-xL expression.

Conclusions:

  • BMP4 exhibits anti-proliferative and pro-apoptotic effects on glioma stem cells.
  • BMP4 represents a promising therapeutic target for novel GSC-based glioma treatments.

More Related Videos

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion09:36

Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion

Published on: August 29, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...